Back to NewsPatent Maintenance Fees Accounting Treatment: GAAP vs IFRSNovember 2026

Patent Maintenance Fees Accounting Treatment: GAAP vs IFRS

The accounting treatment of patent maintenance fees is simple in almost every real company: expense them in the period you pay them. Debit an operating expense, credit the bank, and the patent's carrying amount does not move.

That is the right default. It is not, however, the absolute rule that much of this search result claims, and the difference matters to anyone signing financial statements. Under US GAAP the treatment of renewal costs is an accounting policy you must disclose. Under IFRS capitalisation is rare rather than banned. In Germany the commercial accounts and the tax accounts can part company on the same patent.

Here is the treatment by framework, the entries, and the one place where this small fee touches a much bigger number: your balance sheet at the moment you decide to renew, lapse or sell.

The short answer

CostUS GAAPIFRS (IAS 38)Germany (HGB)
Maintenance or renewal fee on a granted patentNormally expensed; disclosed policyExpensed in almost all casesBooked as operating expense
External cost to obtain the patentCapitalised if future benefit is probable; often expensed in practicePart of cost once recognition criteria are metOption for self-created assets
Purchased patentCapitalisedCapitalisedCapitalised
Legal cost of defending the patentCapitalised only if value increases and success is probableExpensed as maintaining the assetAsk your auditor

The rest of this article is the reasoning behind that table. For a different question, whether the fee reduces your taxable income, see how renewal fees are treated for tax in the US and Germany. Book treatment and tax treatment are separate decisions.

Two confident answers, both overstated

Search the phrase and you get two opposite claims.

A startup finance guide says flatly that you cannot capitalise a renewal, and that under both US GAAP and IFRS these recurring fees should be expensed as incurred. A homework help page says the reverse: renewal fees are capital expenditure and should be added to the carrying amount of the patent, on the reasoning that they extend the asset's life.

The second answer gets the economics wrong. A renewal fee does not give you a longer or broader patent. It stops a right you already hold from ending early, which is the definition of maintaining an asset.

The first answer gets the outcome right but overstates the authority. The practical result is expense. The text behind it is more nuanced, and a finance lead who repeats "GAAP prohibits it" to an auditor will be corrected.

US GAAP: a policy you have to disclose

The clearest evidence sits in the disclosure section of ASC 350-30. Paragraph 350-30-50-2 requires every entity to disclose its accounting policy on the treatment of costs incurred to renew or extend the term of a recognized intangible asset, and adds a further disclosure "for entities that capitalize renewal or extension costs".

A codification does not write a disclosure for entities doing something it forbids. So capitalising is contemplated. That does not make it the common answer, and it does not make it the right answer for a routine patent office fee.

Look at what patent-heavy filers actually do. InterDigital, whose business is licensing patents, states that it capitalises external costs to obtain issued patents and expenses the costs of maintaining and defending them after issuance. Document Security Systems wrote in its 2011 accounts that costs to renew or extend recognised intangibles, including patent annuities and fees, are expensed as incurred. None of the annual report policies we read capitalised a maintenance fee.

What to do: expense the fee, and make sure your policy note actually says so. If your statements present a recognised patent and are silent on renewal costs, that is the gap to close, not the debit.

IFRS: "only rarely"

IAS 38 gets to the same place by a more direct route. Paragraph 20 says most subsequent expenditure is likely to maintain the expected future economic benefits of an existing intangible asset, so only rarely will it be recognised in the carrying amount. A patent renewal fee is a textbook maintaining cost.

The same standard has one sentence worth knowing. Paragraph 96 says that if the cost of renewal is significant compared with the benefits expected from renewal, it represents in substance the cost of acquiring a new asset at the renewal date. That wording fits a contract or licence renewed at a real price. A patent annuity is almost never significant against what the renewed term must be worth to justify paying it, so do not expect this to rescue a capitalisation policy.

There is also no way back. IAS 38 says expenditure previously recognised as an expense may not be reinstated as part of the asset's cost later. If you expensed ten years of annuities, they stay expensed, however valuable the patent turns out to be.

Germany: HGB and the tax balance sheet

German practice treats the fee as plainly operating. Haufe's booking guide has the annual fee go to Sonstige Aufwendungen betrieblich und regelmäßig, account 4905 in SKR 03 or 6304 in SKR 04, against the bank.

The wider asset is where the two sets of books diverge. Section 248(2) HGB allows self-created intangible fixed assets to be shown in the balance sheet, and that option covers development costs but not research costs. The tax balance sheet is stricter: section 5(2) EStG bars self-created intangibles, so development spend and the cost of securing legal protection are recorded as expense. A German company using the option therefore runs a difference between the two, while the renewal fee sits in expense on both.

The entries

Plain expense, the default. Debit patent maintenance expense or other operating expense; credit bank. Amounts this small and recurring are usually expensed on materiality grounds, and that is before any standard has to be argued.

The prepaid question. Here is the point the ranking pages skip. These fees are paid ahead of the period they protect. US fees are the 3.5, 7.5 and 11.5 year fees, and each one carries the patent roughly four years. European renewal fees are due in advance on a yearly basis from the third year after filing.

So if the amounts are material, should the unexpired part sit in prepaid expenses at year end? We found no patent-specific rule either way. The nearest published analogy is outside patents: a mining company records recurring annual renewal fees on its claims as other current assets and expenses them over the year.

An illustration, with invented figures: a EUR 1,200 annuity covering the twelve months from 1 October, in a company with a December year end, would give EUR 300 of expense this year and EUR 900 of prepaid. This is timing inside a short period, not capitalisation into the patent. For one patent nobody will care. For a portfolio with hundreds of annuities, agree a policy with your auditor once and apply it consistently.

Fees before grant are a different animal

A US maintenance fee can only arise on an issued patent. A European renewal fee starts while the application is still pending, so it can fall before the asset is finished.

That matters under IFRS because paragraph 20 speaks of spending after initial recognition or after completion of an internally generated asset, and because paragraph 66 lists fees to register a legal right among the directly attributable costs of an internally generated intangible. If a project already meets the development recognition criteria, a pre-grant renewal fee is at least arguable as part of cost. That is our reading, not settled guidance, so treat it as a question for your auditor.

For most small companies it never gets that far. PwC's life sciences guide notes that patent application costs may in theory be capitalised but in practice are expensed where commercialisation is uncertain, and capitalising requires a probable future economic benefit. A pending application with no product is the uncertain case.

Where the fee actually moves the numbers

The fee itself is small. The decision it forces is not, because a renewal deadline is also an accounting event for any patent with a carrying amount.

Useful life. Under ASC 350-30, the useful life of an asset based on legal rights cannot extend beyond those rights, and a material level of required maintenance relative to the carrying amount may suggest a very limited useful life. IAS 38 paragraph 94 likewise includes renewal periods only with evidence of renewal without significant cost. Deciding not to pay the next fee therefore shortens the life you are amortising over.

Disclosure. US GAAP also asks for information on how your intent or ability to renew affects expected future cash flows. A portfolio review that culls families is not only a cost decision. If you are running one, our notes on patent portfolio pruning cover the keep or drop logic, and what happens when a patent is abandoned covers the legal end of it.

Lapse. IAS 38 requires derecognition when no future economic benefits are expected from use or disposal, so any remaining carrying amount goes to profit or loss when the patent is allowed to die.

Sale. The gain is net disposal proceeds less carrying amount, and it is not revenue. We have covered where that gain and the cash land in your statements separately.

What the balance sheet will not tell a buyer

Follow the rules above to their conclusion and you get an odd result. A self-filed patent whose costs were expensed, with every annuity expensed after them, can sit at zero on the balance sheet while being the most valuable thing the company owns. Meanwhile, each fee you pay shows up only as a cost. On paper, keeping the patent alive looks like pure loss.

Do not let that framing make the renewal decision. Book value here records the accounting route, not the asset. What decides it is what the patent would fetch set against what the remaining fees will cost over the patent's life, and we have set out that renew, abandon or monetise decision in full.

If the answer is that you would rather sell than keep paying, a brokered sale should not become one more cost with no result attached: our brokerage commission is paid by the seller on completion, with a minimum of EUR 5,000 per completed transaction, and no sale means no fee.

This article is general information on how the cited standards and sources describe these costs. It is not accounting or tax advice, and your auditor's view of your facts takes priority.

FAQ

Is a patent renewal fee capital or revenue expenditure? Revenue expenditure in almost every case. It maintains a right you already hold and does not create a longer or better one, which is why it goes through profit or loss rather than onto the balance sheet.

Can we capitalise past maintenance fees once the patent proves valuable? Not under IFRS, because amounts already recognised as an expense cannot be reinstated in the asset's cost. A later valuation or sale will show the value, but the earlier fees stay expensed.

Are patent defence costs treated like maintenance fees? Not quite. Under US GAAP, PwC's guide allows capitalising external defence costs only when a successful defence is probable and the expected benefit increases, and a defence that merely maintains value is expensed. An IFRS worked example expenses defence costs because they maintain the asset.

Who books the fee on a licensed patent? Whoever bears the cost under the licence, and the treatment is not automatic. Artelo Biosciences told SEC staff in 2018 that it would keep evaluating the expense on licensed patents and maintenance fees, and capitalise under ASC 350 only once it could bring a product to market.

Does the book treatment decide the tax treatment? No. The two run on separate rules, and in Germany the tax balance sheet bars self-created patents even where the commercial accounts use the capitalisation option. Ask both questions separately.

We use essential cookies to operate this website and, with your consent, optional cookies to understand site usage. You can accept or decline non-essential cookies at any time. See our Impressum for our contact and legal details.